{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:01:48Z","timestamp":1790197308390,"version":"4.1.0"},"reference-count":46,"publisher":"American Chemical Society (ACS)","issue":"7","license":[{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_termsofuse.html"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Resistance in Gram-negative bacteria to \u03b2-lactam drugs is mediated primarily by the expression of \u03b2-lactamases, and co-dosing of \u03b2-lactams with a \u03b2-lactamase inhibitor (BLI) is a clinically proven strategy to address resistance. New \u03b2-lactamases that are not impacted by existing BLIs are spreading and creating the need for development of novel broader spectrum BLIs. IID572 is a novel broad spectrum BLI of the diazabicyclooctane (DBO) class that is able to restore the antibacterial activity of piperacillin against piperacillin\/tazobactam-resistant clinical isolates. IID572 is differentiated from other DBOs by its broad inhibition of \u03b2-lactamases and the lack of intrinsic antibacterial activity.<\/jats:p>","DOI":"10.1021\/acsinfecdis.9b00031","type":"journal-article","created":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T17:58:02Z","timestamp":1552413482000},"page":"1045-1051","source":"Crossref","is-referenced-by-count":29,"title":["IID572: A New Potentially Best-In-Class \u03b2-Lactamase\nInhibitor"],"prefix":"10.1021","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7250-2526","authenticated-orcid":true,"given":"Folkert","family":"Reck","sequence":"first","affiliation":[{"name":"Novartis Institutes for BioMedical Research , 5300 Chiron Way , , ,","place":["Emeryville, California, United States, 94608"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alun","family":"Bermingham","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research , 5300 Chiron Way , , ,","place":["Emeryville, California, United States, 94608"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne","family":"Blais","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research , 5300 Chiron Way , , ,","place":["Emeryville, California, United States, 94608"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Casarez","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research , 5300 Chiron Way , , ,","place":["Emeryville, California, United States, 94608"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Colvin","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue , , ,","place":["Cambridge, Massachusetts, United States, 02139"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9858-9818","authenticated-orcid":true,"given":"Charles R.","family":"Dean","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research , 5300 Chiron Way , , ,","place":["Emeryville, California, United States, 94608"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Furegati","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research , , Klybeckstrasse 141 , ,","place":["Basel, Switzerland, 4057"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Gamboa","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research , 5300 Chiron Way , , ,","place":["Emeryville, California, United States, 94608"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellena","family":"Growcott","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research , 5300 Chiron Way , , ,","place":["Emeryville, California, United States, 94608"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Li","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research , 5300 Chiron Way , , ,","place":["Emeryville, California, United States, 94608"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lopez","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research , 5300 Chiron Way , , ,","place":["Emeryville, California, United States, 94608"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Metzger","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research , 5300 Chiron Way , , ,","place":["Emeryville, California, United States, 94608"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Nocito","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research , , Klybeckstrasse 141 , ,","place":["Basel, Switzerland, 4057"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Ossola","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research , , Klybeckstrasse 141 , ,","place":["Basel, Switzerland, 4057"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaci","family":"Phizackerley","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research , 5300 Chiron Way , , ,","place":["Emeryville, California, United States, 94608"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dita","family":"Rasper","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research , 5300 Chiron Way , , ,","place":["Emeryville, California, United States, 94608"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Shaul","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research , 5300 Chiron Way , , ,","place":["Emeryville, California, United States, 94608"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Shen","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research , 5300 Chiron Way , , ,","place":["Emeryville, California, United States, 94608"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Simmons","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research , 5300 Chiron Way , , ,","place":["Emeryville, California, United States, 94608"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dazhi","family":"Tang","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research , 5300 Chiron Way , , ,","place":["Emeryville, California, United States, 94608"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyuto","family":"Tashiro","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research , 5300 Chiron Way , , ,","place":["Emeryville, California, United States, 94608"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Yue","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research , 5300 Chiron Way , , ,","place":["Emeryville, California, United States, 94608"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2019,3,12]]},"reference":[{"key":"2026090313164576800_cit1","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/S1473-3099(14)70780-7","article-title":"Global antibiotic\nconsumption 2000 to 2010: an analysis of national pharmaceutical sales\ndata","volume":"14","author":"Van Boeckel","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"2026090313164576800_cit2","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1146\/annurev-micro-090110-102911","article-title":"Epidemiological\nexpansion, structural studies, and\nclinical challenges of new \u03b2-lactamases from Gram-negative bacteria","volume":"65","author":"Bush","year":"2011","journal-title":"Annu. Rev. Microbiol."},{"key":"2026090313164576800_cit3","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1093\/cid\/cix893","article-title":"Carbapenemase-Producing\nOrganisms:\nA Global Scourge","volume":"66","author":"Bonomo","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"2026090313164576800_cit4","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.bmcl.2018.01.006","article-title":"Optimization of novel monobactams with activity against carbapenem-resistant\nEnterobacteriaceae - Identification of LYS228","volume":"28","author":"Reck","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026090313164576800_cit5","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1128\/AAC.00540-16","article-title":"Changes\nin the frequencies\nof \u03b2-lactamase genes among Enterobacteriaceae isolates in U.S.\nHospitals, 2012 to 2014: activity of ceftazidime-avibactam tested\nagainst \u03b2-lactamase-producing isolates","volume":"60","author":"Castanheira","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090313164576800_cit6","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1093\/jac\/dkw561","article-title":"In vitro activity of\nceftazidime\/avibactam against urinary isolates from patients in a\nPhase 3 clinical trial programme for the treatment of complicated\nurinary tract infections","volume":"72","author":"Stone","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"2026090313164576800_cit7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-Avibactam:\na Novel Cephalosporin\/\u03b2-lactamase\nInhibitor Combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"},{"key":"2026090313164576800_cit8","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/phar.1622","article-title":"The \u03b2-Lactams\nStrike Back:\nCeftazidime-Avibactam","volume":"35","author":"Zasowski","year":"2015","journal-title":"Pharmacotherapy"},{"key":"2026090313164576800_cit9","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1093\/jac\/dkx179","article-title":"Emergence of ceftazidime\/avibactam non-susceptibility\nin an MDR Klebsiella pneumoniae isolate","volume":"72","author":"Both","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"2026090313164576800_cit10","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity,\nand emergence of ceftazidime-avibactam resistance among patients treated\nfor carbapenem-resistant enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"2026090313164576800_cit11","doi-asserted-by":"publisher","first-page":"e02101-17","DOI":"10.1128\/AAC.02101-17","article-title":"Successive\nEmergence of Ceftazidime-Avibactam Resistance through Distinct Genomic\nAdaptations in blaKPC-2-Harboring Klebsiella pneumoniae Sequence Type 307 Isolates","volume":"62","author":"Giddins","year":"2018","journal-title":"Antimicrob. Agents\nChemother."},{"key":"2026090313164576800_cit12","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1128\/AAC.02184-15","article-title":"Interactions of OP0595,\na novel triple-action diazabicyclooctane, with \u03b2-lactams against\nOP0595-resistant Enterobacteriaceae mutants","volume":"60","author":"Livermore","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090313164576800_cit13","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/jac\/dkw593","article-title":"In vitro activity\nof cefepime\/zidebactam (WCK 5222) against Gram-negative bacteria","volume":"72","author":"Livermore","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"2026090313164576800_cit14","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1128\/AAC.02102-15","article-title":"Distinctive\nbinding of avibactam to penicillin-binding proteins of gram-negative\nand gram-positive bacteria","volume":"60","author":"Asli","year":"2016","journal-title":"Antimicrob. Agents\nChemother."},{"key":"2026090313164576800_cit15","doi-asserted-by":"publisher","first-page":"17104","DOI":"10.1038\/nmicrobiol.2017.104","article-title":"ETX2514 is a broad-spectrum\n\u03b2-lactamase inhibitor for the treatment of drug-resistant Gram-negative\nbacteria including Acinetobacter baumannii","volume":"2","author":"Durand-Reville","year":"2017","journal-title":"Nat. Microbiol."},{"key":"2026090313164576800_cit16","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1093\/jac\/dkv239","article-title":"Activity of OP0595\/\u03b2-lactam\ncombinations against Gram-negative bacteria with extended-spectrum,\nAmpC and carbapenem-hydrolysing \u03b2-lactamases","volume":"70","author":"Livermore","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"2026090313164576800_cit17","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.mib.2011.07.026","article-title":"Diazabicyclooctanes\n(DBOs): a potent new class of non-\u03b2-lactam \u03b2-lactamase\ninhibitors","volume":"14","author":"Coleman","year":"2011","journal-title":"Curr. Opin. Microbiol."},{"key":"2026090313164576800_cit18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1021\/acs.oprd.7b00381","article-title":"Improved Preparation\nof a Key Hydroxylamine Intermediate for Relebactam: Rate Enhancement\nof Benzyl Ether Hydrogenolysis with DABCO","volume":"22","author":"Yin","year":"2018","journal-title":"Org.\nProcess Res. Dev."},{"key":"2026090313164576800_cit19","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1021\/acs.oprd.6b00268","article-title":"Development of a Manufacturing Route\nto Avibactam,\na \u03b2-Lactamase Inhibitor","volume":"20","author":"Ball","year":"2016","journal-title":"Org. Process\nRes. Dev."},{"key":"2026090313164576800_cit20","doi-asserted-by":"publisher","first-page":"10886","DOI":"10.1021\/ja505964r","article-title":"Carboxylic\nAcids as A Traceless Activation Group for Conjugate Additions: A Three-Step\nSynthesis of (\u00b1)-Pregabalin","volume":"136","author":"Chu","year":"2014","journal-title":"J. Am. Chem.\nSoc."},{"key":"2026090313164576800_cit21","unstructured":"Casarez, A., Furegati, M., Koch, M., Lin, X., Ossola, F., Reck, F., Simmons, R. L., and Zhu, Q. (2018) U.S. Pat. Appl. Publ. US20180086762."},{"key":"2026090313164576800_cit22","volume-title":"CLSI\nMethods for dilution antimicrobial susceptibility tests for bacteria\nthat grow aerobically: approved standard","year":"2015","edition":"10th"},{"key":"2026090313164576800_cit23","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1128\/AAC.01722-10","article-title":"Activity of NXL104\nin combination with \u03b2-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum \u03b2-lactamases\nand class C \u03b2-lactamases","volume":"55","author":"Lagace-Wiens","year":"2011","journal-title":"Antimicrob.\nAgents Chemother."},{"key":"2026090313164576800_cit24","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1093\/jac\/dkv166","article-title":"OP0595, a new diazabicyclooctane: mode of action as\na serine \u03b2-lactamase inhibitor, antibiotic and \u03b2-lactam\n\u2019enhancer\u2019","volume":"70","author":"Morinaka","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"2026090313164576800_cit25","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1021\/acs.jmedchem.8b00091","article-title":"Strategic Approaches\nto Overcome\nResistance against Gram-Negative Pathogens Using \u03b2-Lactamase\nInhibitors and \u03b2-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes\nWCK 5153, Zidebactam (WCK 5107), and WCK 4234","volume":"61","author":"Papp-Wallace","year":"2018","journal-title":"J. Med. Chem."},{"key":"2026090313164576800_cit26","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1093\/jac\/dkt178","article-title":"Activity of MK-7655\ncombined with\nimipenem against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"68","author":"Livermore","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"2026090313164576800_cit27","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of a Cyclic Boronic Acid \u03b2-Lactamase\nInhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases","volume":"58","author":"Hecker","year":"2015","journal-title":"J. Med. Chem."},{"key":"2026090313164576800_cit28","doi-asserted-by":"publisher","first-page":"e02228-17","DOI":"10.1128\/AAC.02228-17","article-title":"Phase 1 Study of\nthe Safety, Tolerability,\nand Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination\nfollowing Single and Multiple Doses in Healthy Adult Subjects","volume":"62","author":"Rubino","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090313164576800_cit29","doi-asserted-by":"publisher","first-page":"e00280-18","DOI":"10.1128\/AAC.00280-18","article-title":"Pharmacokinetics, Safety, and Tolerability of Single\nand Multiple Doses of Relebactam, a \u03b2-Lactamase Inhibitor, in\nCombination with Imipenem and Cilastatin in Healthy Participants","volume":"62","author":"Rhee","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090313164576800_cit30","doi-asserted-by":"publisher","first-page":"e638","DOI":"10.1016\/j.ijid.2013.01.030","article-title":"The impact of the\nincreased use of piperacillin\/tazobactam on the selection of antibiotic\nresistance among invasive Escherichia coli and Klebsiella pneumoniae isolates","volume":"17","author":"Lee","year":"2013","journal-title":"Int.\nJ. Infect. Dis."},{"key":"2026090313164576800_cit31","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1128\/AAC.00693-09","article-title":"Inhibitor resistance in the KPC-2\n\u03b2-lactamase, a preeminent property of this class A \u03b2-lactamase","volume":"54","author":"Papp-Wallace","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090313164576800_cit32","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1128\/AAC.00756-10","article-title":"Activities\nof NXL104 combinations\nwith ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae","volume":"55","author":"Livermore","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090313164576800_cit33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1021\/acsinfecdis.5b00007","article-title":"Molecular\nMechanism of Avibactam-Mediated \u03b2-Lactamase Inhibition","volume":"1","author":"King","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"2026090313164576800_cit34","doi-asserted-by":"publisher","first-page":"11663","DOI":"10.1073\/pnas.1205073109","article-title":"Avibactam is a covalent,\nreversible, non-\u03b2-lactam \u03b2-lactamase inhibitor","volume":"109","author":"Ehmann","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2026090313164576800_cit35","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1021\/acsinfecdis.7b00113","article-title":"Reversibility\nof covalent, broad-spectrum serine \u03b2-lactamase inhibition by\nthe diazabicyclooctenone ETX2514","volume":"3","author":"Shapiro","year":"2017","journal-title":"ACS Infect.\nDis."},{"key":"2026090313164576800_cit36","doi-asserted-by":"publisher","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","article-title":"Kinetics of Avibactam\nInhibition against Class A, C, and D \u03b2-Lactamases","volume":"288","author":"Ehmann","year":"2013","journal-title":"J. Biol. Chem."},{"key":"2026090313164576800_cit37","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1128\/AAC.04552-14","article-title":"Profiling of beta-lactam selectivity for penicillin-binding\nproteins in Escherichia coli strain DC2","volume":"59","author":"Kocaoglu","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090313164576800_cit38","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/jac\/dku568","article-title":"Characterization of Escherichia coli\nNDM isolates with decreased susceptibility to aztreonam\/avibactam:\nrole of a novel insertion in PBP3","volume":"70","author":"Alm","year":"2015","journal-title":"J. Antimicrob.\nChemother."},{"key":"2026090313164576800_cit39","doi-asserted-by":"publisher","first-page":"e01200-18","DOI":"10.1128\/AAC.01200-18","article-title":"The monobactam\nLYS228: mode of action and mechanisms decreasing in vitro susceptibility\nof Escherichia coli and Klebsiella pneumoniae","author":"Dean","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090313164576800_cit40","doi-asserted-by":"publisher","first-page":"e00389","DOI":"10.1128\/AAC.00389-17","article-title":"Unusual Escherichia coli PBP 3 Insertion Sequence Identified from\na Collection of Carbapenem-Resistant Enterobacteriaceae Tested In\nVitro with a Combination of Ceftazidime-, Ceftaroline-, or Aztreonam-Avibactam","volume":"61","author":"Zhang","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090313164576800_cit41","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/jac\/33.1.7","article-title":"Molecular\naspects of methicillin resistance in Staphylococcus aureus","volume":"33","author":"de Lencastre","year":"1994","journal-title":"J. Antimicrob. Chemother."},{"key":"2026090313164576800_cit42","unstructured":"Ouchi, S., Matsumoto, K., Uchida, M., Shibasaki, S., Tsuchiya, T., and Ida, T. (September 5\u20139, 2014)  54th Interscience Conference Antimicrobial Agents\nand Chemotherapy (ICAAC), Washington, DC."},{"key":"2026090313164576800_cit43","unstructured":"Chavan, R. P., Patel, A. M., Zope, V. S., Shaikh, J. U., Patil, A. D., Yeole, R. D., and Patel, M. V. (June 16\u201320, 2016) WCK5107 (zidebactam) and WCK5222 (cefepime-zidebactam)\nintravenous pharmacokinetics in beagle dogs. In  56th Interscience Conference Antimicrobial Agents and Chemotherapy\n(ICAAC), Poster Sunday 450."},{"key":"2026090313164576800_cit44","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1098\/rstb.1980.0049","article-title":"The structure\nof beta-lactamases","volume":"289","author":"Ambler","year":"1980","journal-title":"Philos. Trans. R. Soc.,\nB"},{"key":"2026090313164576800_cit45","doi-asserted-by":"publisher","first-page":"4897","DOI":"10.1073\/pnas.78.8.4897","article-title":"ampC cephalosporinase\nof Escherichia coli K-12 has\na different evolutionary origin from that of beta-lactamases of the\npenicillinase type","volume":"78","author":"Jaurin","year":"1981","journal-title":"Proc. Natl. Acad. Sci. U.\nS. A."},{"key":"2026090313164576800_cit46","doi-asserted-by":"publisher","first-page":"7378","DOI":"10.1073\/pnas.84.21.7378","article-title":"Precise insertion of antibiotic resistance\ndeterminants into Tn21-like transposons: nucleotide sequence of the\nOXA-1 beta-lactamase gene","volume":"84","author":"Ouellette","year":"1987","journal-title":"Proc. Natl. Acad.\nSci. U. S. A."}],"container-title":["ACS Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsinfecdis.9b00031","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/aidcbc\/article-pdf\/5\/7\/1045\/67303461\/acsinfecdis.9b00031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/aidcbc\/article-pdf\/5\/7\/1045\/67303461\/acsinfecdis.9b00031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:16:55Z","timestamp":1788455815000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/aidcbc\/article\/5\/7\/1045\/607837\/IID572-A-New-Potentially-Best-In-Class-Lactamase"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,12]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,3,12]]},"published-print":{"date-parts":[[2019,7,12]]}},"URL":"https:\/\/doi.org\/10.1021\/acsinfecdis.9b00031","relation":{},"ISSN":["2373-8227"],"issn-type":[{"value":"2373-8227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,12]]}}}